Valneva's Shares Approach Technical Support After a 38% Decline Over Three Months
The stock of the Nantes-based vaccine specialist fell sharply at the start of the session this Monday, April 13, in a Parisian market that was also trending downward. Valneva has declined by 3.14% to 2.591 euros, extending a bearish trend that has been marked in recent months. The stock is now very close to its technical support threshold, a level monitored by operators.
Valneva's stock has lost 3.14% compared to last Friday's close (2.68 euros), now standing at 2.591 euros. This new drop is part of a prolonged decline: the stock has lost 4.39% over the last seven days and 38.54% over three months. Over a year, the performance remains negative at -6.6%. The price is now very close to the identified support threshold at 2.58 euros. A downward breach of this level could pave the way for a continuation of the correction, with resistance significantly higher at 4.93 euros. The CAC 40 is down 0.95% at 8,181.44 points during the session, while the SBF 120 loses 0.94%, illustrating a generally unfavorable environment. In the health sector, Sanofi is down 0.60% and UCB drops 1.13%, confirming broader selling pressure on European pharmaceutical stocks.
Technical Analysis Perspective
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical analysis standpoint, Valneva's Relative Strength Index (RSI) stands at 29, just below the conventional oversold threshold set at 30. This level indicates intense and persistent selling pressure on the stock. Moreover, the price of 2.591 euros is significantly below its 50-day and 200-day moving averages, established at 4.03 euros and 3.88 euros respectively, confirming the medium and long-term bearish trend. Regarding the calendar, the first quarter 2026 results are expected on May 7, followed by the general meeting scheduled for June 1. These dates could act as catalysts for the stock, in one direction or another. No new elements have specifically explained the day's bearish movement, which fits into the broader trend observed over several weeks on the stock.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
